医学
内科学
三阴性乳腺癌
肿瘤科
危险系数
化疗
乳腺癌
阶段(地层学)
优势比
免疫疗法
癌症
置信区间
生物
古生物学
作者
Yuhan Wei,Wu Yun,Yang Luo,Fei Ma
标识
DOI:10.1016/j.critrevonc.2024.104309
摘要
To assess the efficacy of PD-1/PD-L1 inhibitors combined with chemotherapy for early-stage triple-negative breast cancer (TNBC) patients with different clinical characteristics.Randomized clinical trials for PD-1/PD-L1 inhibitors and chemotherapy combination were included. Pooled analysis of odds ratio (OR) for pathological complete response (pCR) and hazard ratio (HR) for event-free survival (EFS) was conducted overall and for predefined subgroups.The combination of immunotherapy and chemotherapy significantly improved pCR rate in early TNBC patients (OR, 1.77), and the incidence of events was significantly reduced by 37%. Lymph node metastasis was associated with more benefits on pCR (OR[N0], 1.29; OR[N+], 2.57; P = 0.01), while earlier T stage was related to more benefits on EFS (HR[T1-T2], 0.48; HR[T3-T4], 0.85; P = 0.05).The addition of PD-1/PD-L1 inhibitors to chemotherapy offers improved pCR and EFS in early TNBC patients. T and N stages may have implications for the efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI